

Quest is an Alberta-based biotechnology company developing a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, photodynamic therapy, radioimmunotherapy or immunoadjuvants.

Urology Program – Photodynamic Therapy

Prostate cancer is the most common cancer affecting males. Approximately 30% of men over the age of 50 years will have prostate cancer. Currently 1 in 10 North American males can expect to be afflicted by prostate cancer and 3% of men will die of this disease. The US market for prostate cancer is estimated at \$1.2 billion US annually.

Prostate cancers are typically slow growing and are relatively resistant to radiotherapy or chemotherapy. The treatment of localized prostate cancer remains controversial. Traditional modalities include radical prostatectomy, radiation treatment and hormonal therapy. All three modalities vary in their associated morbidities and treatment failure rates. Incontinence and impotence are the most common (and most unwelcome) side effects.

Compared to other experimental procedures, photodynamic therapy (PDT) potentially can provide more accurate and predictable light delivery to prostate tissue thereby minimizing toxicities. As well, selective perfusion or accumulation of photosensitizer in the target tissue (prostate) can mitigate the collateral damage to surrounding normal tissue and yield a further advantage for PDT. Therefore, unlike any other treatment modality, PDT with its dual selectivity (light and drug), has the ability to be highly tissue selective, are thereby improve prostate cancer treatment.

Photodynamic Therapy with SL052 - Potential as first line therapy

- Minimally invasive procedure, placement of light fibers through ultrasound guided needles
- Low carcinogenic potential compared to radiation therapy
- Maintain good quality of life – less side effects
- Post-treatment mobilization of immune response

PDT with SL052 also has potential applications in the treatment of benign prostate hyperplasia (BPH) and bladder cancer.

Product	Indication	Status
SL052	Prostate Cancer	Phase I Study In progress
SL052	BPH	Pre-clinical
SL052	Bladder Cancer	Pre-clinical


CONTACT INFORMATION : Dr. Madi Madiyalakan, CEO

Quest PharmaTech Inc. 9407- 20ave, Edmonton, AB T6N 1E5
(780) 448-1400 ext.204 e-mail: madi@questpharmatech.com

www.questpharmatech.com

Selective Delivery of SL052 to Prostate Glands via Intra-Arterial Administration

SL052 can be selectively delivered to the prostate glands by intra-arterial administration of the drug. Using a model photosensitizer in a dog prostate model, therapeutic ratios of >100:1 between prostate and surrounding tissue has been achieved. This approach maximizes the therapeutic benefits while minimizes any untoward side effects in non-target organs.




Phase I Clinical Trial In Progress

A Two Stage, Uncontrolled, Phase I Intra-Prostatic Drug Distribution and Light Dose Escalation Study to Assess the Prostatic Localization, Safety, Tolerability, and Preliminary Efficacy of Interstitial Photodynamic Therapy with SL052 in Subjects with Localized Prostate Cancer

	Stage 1	Stage 2
Objectives	Assess prostatic localization of SL052 after Intra-arterial administration	<ul style="list-style-type: none"> Assess safety and tolerability of interstitial PDT with SL052 Assess efficacy of PDT treatment
Assessments	Visual Examination Fluorescent Microscopy	<ul style="list-style-type: none"> Safety: Adverse events, concomitant medications, urinalysis, hematology, serum chemistry, and sexual function Pharmacokinetics: Plasma concentration and metabolites Efficacy: Prostate biopsy, PSA, MRI
Number of Subjects	Up to 6 subjects undergoing radical prostatectomy	<ul style="list-style-type: none"> 3 groups of 3 patients treated with ascending light dose with single light fiber 1 group of 3 patients with highest tolerable light dose with multiple fibers



Mouse Tumor Model (Control Day 0)



Mouse Tumor Model SL052 PDT Treated Day 35



Effect of SL052 and PDT Treatment on Dog Prostate

PET Imaging Pre and Post PDT Treatment

